神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NBIX 神经分泌生物科学

未开盘 07-19 16:00:00 EDT

145.69

+1.55

+1.08%

盘后145.69

+0.000.00%

19:54 EDT

最高146.30	最低143.09	成交量60.00万
今开144.47	昨收144.14	日振幅2.23%
总市值146.62亿	流通市值144.84亿	总股本1.01亿
成交额8,689万	换手率0.60%	流通股本9,942万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

{"stockData":{"symbol":"NBIX","market":"US","secType":"STK","nameCN":"神经分泌生物科学","latestPrice":145.69,"timestamp":1721419200000,"preClose":144.14,"halted":0,"volume":600041,"hourTrading":{"tag":"盘后","latestPrice":145.69,"preClose":145.69,"latestTime":"19:54 EDT","volume":10222,"amount":1489374.372,"timestamp":1721433284089},"delay":0,"floatShares":99416980,"shares":100637227,"eps":3.602348,"marketStatus":"未开盘","marketStatusCode":0,"change":1.55,"latestTime":"07-19 16:00:00 EDT","open":144.47,"high":146.3,"low":143.09,"amount":86890983.14481,"amplitude":0.02227,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":3.602348,"exchange":"NASDAQ","tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1721635200000},"adr":0,"listingDate":832824000000,"adjPreClose":144.14,"adrRate":0,"preHourTrading":{"tag":"盘前","latestPrice":148.29,"preClose":144.14,"latestTime":"09:11 EDT","volume":13,"amount":1914.66002,"timestamp":1721394674123},"postHourTrading":{"tag":"盘后","latestPrice":145.69,"preClose":145.69,"latestTime":"19:54 EDT","volume":10222,"amount":1489374.372,"timestamp":1721433284089},"volumeRatio":0.9766009761004151,"impliedVol":0.5283,"impliedVolPercentile":0.992},"requestUrl":"/m/hq/s/NBIX/wiki","defaultTab":"wiki","newsList":[{"id":"2450385481","title":"美国研究综述-Nvidia、高通、特斯拉","url":"https://stock-news.laohu8.com/highlight/detail?id=2450385481","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450385481?lang=zh_cn&edition=full","pubTime":"2024-07-10 15:41","pubTimestamp":1720597288,"startTime":"0","endTime":"0","summary":"    路透7月10日 - 华尔街证券分析师周三调整了对几家美国上市公司的评级和目标价，其中包括Nvidia、高通和特斯拉。* Nvidia Corp   ：KeyBanc将目标价上调至180美元 * 高通公司   ：KeyBanc将目标价上调至225美元  * 特斯拉  ：汇丰银行将目标价从120美元上调至130美元  以下是路透周三报道的美国公司研究报告摘要。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DNLI","AMD","QCOM","GL","BK4559","SAIC","RNG","TWLO","SG9999014575.USD","KO","JXN","BK4177","CACI","FIVN","MPWR","MU","AFL","LZ","PRU","LGIH","RCUS","KDP","AMP","PFG","LDOS","ON","IE0004445015.USD","LU1169590202.USD","CRUS","SAGE","SG9999015986.USD","TSLL","TSLA","BAH","LU2237443382.USD","MOH","RGA","NICE","CNO","CNC","PRI","LU2237443549.SGD","NVDA","ENLC","BK4550","EQH","MRVL","DVN","BHF","NBIX"],"gpt_icon":1},{"id":"2441454257","title":"神经分泌生物科学盘中异动 股价大跌5.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2441454257","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441454257?lang=zh_cn&edition=full","pubTime":"2024-06-05 03:56","pubTimestamp":1717531001,"startTime":"0","endTime":"0","summary":"北京时间2024年06月05日03时56分，神经分泌生物科学股票出现波动，股价快速下跌5.06%。截至发稿，该股报132.84美元/股，成交量90.0722万股，换手率0.90%，振幅4.67%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.29%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605035641af8bf2d9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240605035641af8bf2d9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2065171311.SGD","LU0109394709.USD","LU2065171402.SGD","LU2065170008.USD","LU0320765992.SGD","NBIX","LU2065169927.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2439202115","title":"神经分泌生物科学盘中异动 急速下挫5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2439202115","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439202115?lang=zh_cn&edition=full","pubTime":"2024-05-29 21:39","pubTimestamp":1716989968,"startTime":"0","endTime":"0","summary":"北京时间2024年05月29日21时39分，神经分泌生物科学股票出现波动，股价急速下挫5.07%。神经分泌生物科学股票所在的制药行业中，整体跌幅为0.10%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。消息层面，截至21时39分，《瑞银：维持Neurocrine Biosciences评级，由买入调整至买入评级, 目标价由174.00美元调整至193.00美元。》资讯为影响神经分泌生物科学的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240529213928941eae4e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240529213928941eae4e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU0109394709.USD","LU2065169927.USD","LU2065171311.SGD","LU0320765992.SGD","LU2065170008.USD","LU2065171402.SGD","NBIX","LU0889565916.HKD"],"gpt_icon":0},{"id":"2439778538","title":"更新版 1-Neurocrine 公司创始人兼首席执行官戈尔曼将于 10 月退休","url":"https://stock-news.laohu8.com/highlight/detail?id=2439778538","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439778538?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:33","pubTimestamp":1716928411,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 )) (添加第2-4段中的详细信息)    路透5月28日 - Neurocrine Biosciences    首席执行官凯文-戈尔曼（Kevin Gorman）将于10月11日退休，在他创建公司三十年后，他将由凯尔-加诺（Kyle Gano）接任。Gorman于1992年创立了Neurocrine公司，在2008年被任命为首席执行官之前曾担任过多个领导职务。 凯尔-加诺现任首席业务发展和战略官。收盘后，该公司股价下跌3.2%，报136美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU0109394709.USD","LU0889565916.HKD","LU2065169927.USD","LU2065171402.SGD","LU2065170008.USD","BK4139","LU0320765992.SGD","NBIX"],"gpt_icon":0},{"id":"2439753387","title":"神经分泌生物科学宣布首席执行官继任计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2439753387","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439753387?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:27","pubTimestamp":1716928036,"startTime":"0","endTime":"0","summary":"神经分泌生物科学宣布首席执行官继任计划","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405290427239efba1f8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405290427239efba1f8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065169927.USD","LU2065171402.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","NBIX","LU2065171311.SGD","LU2065170008.USD","BK4139"],"gpt_icon":0},{"id":"2439808533","title":"Neurocrine Biosciences Inc：任命首席业务发展和战略官凯尔·加诺博士为当选首席执行官","url":"https://stock-news.laohu8.com/highlight/detail?id=2439808533","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439808533?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:26","pubTimestamp":1716927983,"startTime":"0","endTime":"0","summary":"Neurocrine Biosciences Inc：任命首席业务发展和战略官凯尔·加诺博士为当选首席执行官","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052904262795710d6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052904262795710d6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0320765992.SGD","LU0889565916.HKD","LU2065171311.SGD","BK4139","LU2065170008.USD","LU0109394709.USD","LU2065171402.SGD","LU2065169927.USD","NBIX"],"gpt_icon":0},{"id":"2439538524","title":"Neurocrine 首席执行官即将退休","url":"https://stock-news.laohu8.com/highlight/detail?id=2439538524","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439538524?lang=zh_cn&edition=full","pubTime":"2024-05-29 04:25","pubTimestamp":1716927905,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透5月28日 - Neurocrine Biosciences   周二表示，凯文-戈尔曼（Kevin Gorman）将于10月11日卸任首席执行官一职，凯尔-加诺（Kyle Gano）将接替他的职务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","LU0320765992.SGD","LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2438754313","title":"瑞银：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由174.00美元调整至193.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2438754313","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2438754313?lang=zh_cn&edition=full","pubTime":"2024-05-28 20:17","pubTimestamp":1716898644,"startTime":"0","endTime":"0","summary":"瑞银：维持Neurocrine Biosciences(NBIX.US)评级，由买入调整至买入评级, 目标价由174.00美元调整至193.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282017279ef94b66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405282017279ef94b66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"2435568188","title":"美国研究综述-Akoya Biosciences、波士顿啤酒公司、胜利资本控股公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2435568188","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435568188?lang=zh_cn&edition=full","pubTime":"2024-05-14 15:22","pubTimestamp":1715671336,"startTime":"0","endTime":"0","summary":"    路透5月14日 - 华尔街证券分析师周二调整了对几家美国上市公司的评级和目标价，其中包括 Akoya Biosciences、波士顿啤酒公司和 Victory Capital Holdings。要点              * Akoya Biosciences Inc   ：Canaccord Genuity将目标价从10美元下调至6美元              * 波士顿啤酒公司   ：杰富瑞将目标价从335美元上调至360美元             * Fortrea Holdings Inc   ：Evercore ISI将目标价从43美元下调至31美元              * Medical Properties Trust Inc   ：加拿大皇家银行将其评级从 \"跑赢大盘 \"下调至 \"行业表现\"。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACLX","VCTR","SG9999011175.SGD","BK4583","CHUY","APDN","BK4203","MPW","SG9999003800.SGD","EMR","BK4568","CTRE","JELD","NHI","LEGN","GPRE","BK4096","BBIO","STZ","JXN","OBDC","CDNA","BHF","FIVE","NOTV","IOVA","FTRE","LU2249611893.SGD","BK4566","BK4120","NGNE","BK4551","CIVB","BK4007","FULC","BMRN","AKYA","MSGE","NBIX","BK4135","SAM","DH","LOB","MRNA","ATLC","NNI","ARIS","CMPX","BK4121","AGL"],"gpt_icon":0},{"id":"2433434648","title":"神经分泌生物科学2024财年第一财季实现净利润43.40百万美元，同比增加156.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2433434648","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2433434648?lang=zh_cn&edition=full","pubTime":"2024-05-06 00:20","pubTimestamp":1714926051,"startTime":"0","endTime":"0","summary":"3月31日，神经分泌生物科学公布财报，公告显示公司2024财年第一财季净利润为43.40百万美元，同比增加156.66%；其中营业收入为5.15亿美元，同比增加22.62%，每股基本收益为0.43美元。机构评级：截至2024年3月31日，当前有25家机构对神经分泌生物科学目标价做出预测，其中目标均价为158.62美元，其中最低目标价为111.00美元，最高目标价为216.00美元。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405060021028b76cb4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405060021028b76cb4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"2432939543","title":"巴克莱：维持Neurocrine Biosciences(NBIX.US)评级，由增持调整至增持评级, 目标价由150.00美元调整至169.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2432939543","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432939543?lang=zh_cn&edition=full","pubTime":"2024-05-03 02:05","pubTimestamp":1714673122,"startTime":"0","endTime":"0","summary":"巴克莱：维持Neurocrine Biosciences(NBIX.US)评级，由增持调整至增持评级, 目标价由150.00美元调整至169.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030205238b6de199&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405030205238b6de199&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0},{"id":"2432396066","title":"神经分泌生物科学盘中异动 股价大涨5.05%报144.49美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2432396066","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432396066?lang=zh_cn&edition=full","pubTime":"2024-05-02 03:11","pubTimestamp":1714590700,"startTime":"0","endTime":"0","summary":"北京时间2024年05月02日03时11分，神经分泌生物科学股票出现异动，股价大幅拉升5.05%。截至发稿，该股报144.49美元/股，成交量78.7129万股，换手率0.78%，振幅6.05%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.50%。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050203114087e853ce&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050203114087e853ce&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LU2065171311.SGD","LU0109394709.USD","LU2065171402.SGD","LU2065170008.USD","LU0320765992.SGD","NBIX","LU2065169927.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2432579434","title":"Neurocrine Biosciences Inc 报告截至一月的季度业绩 - 收益摘要","url":"https://stock-news.laohu8.com/highlight/detail?id=2432579434","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432579434?lang=zh_cn&edition=full","pubTime":"2024-05-01 20:52","pubTimestamp":1714567969,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences Inc   公布的截至1月份的季度调整后每股收益为42美分，高于去年同期的每股收益-79美分。27 位分析师对该季度的平均预期是每股收益 1.01 美元。华尔街预期为每股收益 18 美分至 1.77 美元。* Neurocrine Biosciences 公司公布的本季度每股收益为 42 美分。* 公司报告的季度净收入为 4340 万美元。* Neurocrine Biosciences Inc 的股价本季度下跌了 0.3%，今年迄今为止上涨了 4.4%。华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 154.50 美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX","LU0320765992.SGD","LU2065170008.USD","LU2065171311.SGD","LU2065169927.USD","LU2065171402.SGD","LU0889565916.HKD","LU0109394709.USD","BK4139"],"gpt_icon":0},{"id":"2432346565","title":"更新版 1-Neurocrine Biosciences 的亨廷顿氏症药物获得 FDA 批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2432346565","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432346565?lang=zh_cn&edition=full","pubTime":"2024-05-01 05:48","pubTimestamp":1714513709,"startTime":"0","endTime":"0","summary":"     路透4月30日 - 美国食品和药物管理局 已经批准了 Neurocrine Biosciences 的  INGREZZA药物的颗粒剂 型，用于治疗与亨廷顿氏病相关的运动障碍。亨廷顿氏病是一种遗传性疾病，会导致大脑神经细胞逐渐衰竭，从而导致运动控制能力、认知能力和精神稳定性逐渐下降。INGREZZA于2017年首次获批口服胶囊剂型，用于治疗成人运动障碍迟发性运动障碍和舞蹈症。颗粒剂 \"INGREZZA SPRINKLE \"是为吞咽胶囊有困难的迟发性运动障碍和舞蹈症患者开发的替代药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU2065169927.USD","LU0320765992.SGD","LU2065170008.USD","LU0889565916.HKD","LU2065171311.SGD","NBIX","LU2065171402.SGD","BK4139"],"gpt_icon":0},{"id":"2432539149","title":"FDA 批准 Neurocrine Biosciences 的亨廷顿氏症药物","url":"https://stock-news.laohu8.com/highlight/detail?id=2432539149","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2432539149?lang=zh_cn&edition=full","pubTime":"2024-05-01 05:31","pubTimestamp":1714512688,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    路透4月30日 - 美国食品和药物管理局(FDA) 周二表示，该公司已批准了 Neurocrine Biosciences公司  治疗亨廷顿氏病相关运动障碍的颗粒剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","LU2065169927.USD","NBIX","LU2065170008.USD","BK4139","LU0320765992.SGD","LU0109394709.USD","LU2065171311.SGD","LU0889565916.HKD"],"gpt_icon":0},{"id":"2431515478","title":"Neurocrine Biosciences Inc   预计每股收益1.01美元 - 财报前瞻","url":"https://stock-news.laohu8.com/highlight/detail?id=2431515478","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431515478?lang=zh_cn&edition=full","pubTime":"2024-04-29 20:27","pubTimestamp":1714393620,"startTime":"0","endTime":"0","summary":"   * Neurocrine Biosciences Inc     5月1日发布的截至2023年12月31日的财报显示，该公司的季度营收预计将有所增长。* 根据LSEG的数据，24位分析师的平均预期显示，这家总部位于加利福尼亚州圣地亚哥的公司的营收将从去年同期的4.204亿美元增至5.11974亿美元，增幅为21.8%。* LSEG 分析师对 Neurocrine Biosciences Inc 的平均预期为每股收益 1.01 美元。* 华尔街对 Neurocrine Biosciences Inc 的 12 个月目标价中位数为 154.50 美元，高于其上次收盘价 135.99 美元。4月29日 - 上一季度业绩。除非另有说明，所有数字均以美元计。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NBIX"],"gpt_icon":0},{"id":"2429438171","title":"Neurocrine Biosciences(NBIX.US)潜在“first-in-class”小分子疗法达到2期临床终点 显著缓解抑郁症状","url":"https://stock-news.laohu8.com/highlight/detail?id=2429438171","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429438171?lang=zh_cn&edition=full","pubTime":"2024-04-24 10:31","pubTimestamp":1713925868,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，Neurocrine Biosciences(NBIX.US)宣布，在研疗法NBI-1065845在治疗抑郁症(MDD)成年患者的2期临床试验SAVITRI中获得积极顶线数据。NBI-1065845是一款潜在“first-in-class”的AMPA受体正向别构调节剂(PAM)，旨在治疗在抑郁发作中至少对一种抗抑郁药没有应答的MDD患者。NBI-1065845的耐受性总体良好，头痛是最常见的不良事件。两个剂量的不良事件情况与安慰剂组相当。研究中未报告死亡或严重不良事件，整个研究期间的中止率保持低水平。SAVITRI研究的更多数据将在未来的科学会议上公布。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1108233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0320765992.SGD","LU0109394709.USD","LU2065170008.USD","LU0889565916.HKD","LU2065171402.SGD","LU2065169927.USD","BK4139","LU2065171311.SGD","NBIX"],"gpt_icon":0},{"id":"2429907251","title":"神经分泌生物科学盘中异动 早盘快速拉升8.16%报144.57美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2429907251","media":"自选股智能写手","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429907251?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:32","pubTimestamp":1713879137,"startTime":"0","endTime":"0","summary":"北京时间2024年04月23日21时32分，神经分泌生物科学股票出现波动，股价快速拉升8.16%。截至发稿，该股报144.57美元/股，成交量13.2855万股，换手率0.13%，振幅3.49%。神经分泌生物科学股票所在的制药行业中，整体涨幅为0.81%。神经分泌生物科学公司简介：Neurocrine Biosciences Inc 是一家研究型制药公司。该公司推动中枢神经系统和内分泌相关类别的候选药物的发展。消息层面，截至21时32分，《Needham：重申Neurocrine Biosciences持有评级。》资讯为影响神经分泌生物科学的重要信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042321321787a65b1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024042321321787a65b1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2065169927.USD","LU2065171402.SGD","LU0889565916.HKD","LU0320765992.SGD","LU0109394709.USD","NBIX","LU2065171311.SGD","LU2065170008.USD","BK4139"],"gpt_icon":0},{"id":"2429192203","title":"BUZZ-Neurocrine 因抑郁症治疗在中期试验中取得成功而上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2429192203","media":"Reuters","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2429192203?lang=zh_cn&edition=full","pubTime":"2024-04-23 21:17","pubTimestamp":1713878254,"startTime":"0","endTime":"0","summary":"((自动化翻译由路透提供，请见免责声明 ))    4月23日 - ** Neurocrine Biosciences   股价盘前上涨约5.9%至141.50美元** 该公司称 (link)，其口服药物NBI-1065845在一项评估重度抑郁症患者的中期试验中达到了主要目标 ** 该公司称，该药物在统计学上显著降低了一种抑郁评分量表的总分 ** 公司期待与美国 FDA 会面，讨论该疗法的后期研究** 截至上次收盘，该公司股价年累计上涨了1.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BUZZ","LU0320765992.SGD","LU0889565916.HKD","LU2065171311.SGD","BK4139","LU2065170008.USD","LU0109394709.USD","LU2065171402.SGD","LU2065169927.USD","NBIX"],"gpt_icon":0},{"id":"2428232112","title":"Wedbush：重申Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价147.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2428232112","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2428232112?lang=zh_cn&edition=full","pubTime":"2024-04-18 01:25","pubTimestamp":1713374703,"startTime":"0","endTime":"0","summary":"Wedbush：重申Neurocrine Biosciences(NBIX.US)评级，由优于大市调整至优于大市评级, 目标价147.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418012505878b2263&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240418012505878b2263&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NBIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.neurocrine.com","stockEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":0.1133},{"period":"3month","weight":0.1037},{"period":"6month","weight":0.0606},{"period":"1year","weight":0.488},{"period":"ytd","weight":0.1057}],"compareEarnings":[{"period":"1week","weight":-0.0196},{"period":"1month","weight":0.0009},{"period":"3month","weight":0.1087},{"period":"6month","weight":0.138},{"period":"1year","weight":0.2141},{"period":"ytd","weight":0.155}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Neurocrine Biosciences, Inc.于1992年1月在加利福尼亚州注册成立，并于1996年5月在特拉华州重新注册成立。该公司是一家专注于神经科学的生物制药公司，目的很简单：为有巨大需求的人减轻痛苦，但选择很少。三十年来，该公司运用对神经科学以及大脑和身体系统之间相互联系的独特见解，推进用于治疗未得到充分解决的神经、神经内分泌和神经精神疾病的药物，他们将继续不懈地追求药物，以减轻令人衰弱的疾病和紊乱的负担。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.066296},{"month":2,"riseRate":0.321429,"avgChangeRate":-0.00768},{"month":3,"riseRate":0.428571,"avgChangeRate":-0.006842},{"month":4,"riseRate":0.357143,"avgChangeRate":-0.012064},{"month":5,"riseRate":0.571429,"avgChangeRate":0.045557},{"month":6,"riseRate":0.517241,"avgChangeRate":0.019417},{"month":7,"riseRate":0.482759,"avgChangeRate":-0.001715},{"month":8,"riseRate":0.535714,"avgChangeRate":0.024904},{"month":9,"riseRate":0.571429,"avgChangeRate":0.032175},{"month":10,"riseRate":0.535714,"avgChangeRate":0.029555},{"month":11,"riseRate":0.571429,"avgChangeRate":0.038168},{"month":12,"riseRate":0.642857,"avgChangeRate":0.042544}],"exchange":"NASDAQ","name":"神经分泌生物科学","nameEN":"Neurocrine Biosciences"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"神经分泌生物科学,NBIX,神经分泌生物科学股票,神经分泌生物科学股票老虎,神经分泌生物科学股票老虎国际,神经分泌生物科学行情,神经分泌生物科学股票行情,神经分泌生物科学股价,神经分泌生物科学股市,神经分泌生物科学股票价格,神经分泌生物科学股票交易,神经分泌生物科学股票购买,神经分泌生物科学股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"神经分泌生物科学(NBIX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供神经分泌生物科学(NBIX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}